Summary & Overview
CPT 88342: Immunohistochemistry or Immunocytochemistry, Initial Antibody Stain
CPT code 88342 represents immunohistochemistry or immunocytochemistry procedures, a cornerstone in modern pathology for identifying specific antigens in tissue specimens. This code is widely used in clinical laboratories and pathology departments to support the diagnosis and classification of cancers and other diseases. Nationally, the code is recognized by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, reflecting its broad clinical and reimbursement relevance.
This publication provides a comprehensive overview of 88342, including payer coverage, clinical context, and related coding practices. Readers will gain insight into the procedural scope, typical sites of service, and the importance of immunohistochemical analysis in patient care. The summary also highlights associated modifiers and taxonomies, as well as common ICD-10 diagnoses linked to this code, such as malignant neoplasms of the breast, prostate, lung, colon, and other tissues. Additionally, related CPT codes like 88341 and 88360 are discussed to clarify coding distinctions.
Healthcare professionals, administrators, and policy analysts will find benchmarks, policy updates, and clinical context to inform decision-making and support compliance with payer requirements. The article is structured to deliver key information efficiently, emphasizing the national significance of 88342 in pathology and laboratory medicine.
CPT Code Overview
CPT code 88342 is used to report immunohistochemistry or immunocytochemistry procedures performed on a specimen. This code covers the initial single or multiplex antibody stain, including interpretation and report, as part of pathology and laboratory procedures. The typical site of service for this procedure is a clinical laboratory or pathology department, such as Place of Service 19 or 22. These tests play a critical role in diagnosing and characterizing diseases, particularly various types of neoplasms, by detecting specific antigens in tissue samples.
Clinical & Coding Specifications
Clinical Context
A patient presents with a tissue specimen obtained via biopsy or surgical excision due to suspicion of malignancy, such as a breast mass or prostate lesion. The specimen is sent to the pathology department, where a pathologist performs immunohistochemistry (IHC) using an initial single or multiplex antibody stain to help characterize the nature of the neoplasm. The pathologist interprets the staining results and generates a report to assist in diagnosis, prognosis, or therapeutic decision-making. This procedure is typically performed in a clinical laboratory or pathology department setting.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component (interpretation and report) of the procedure. - Modifier
TC: Used when reporting only the technical component (performance of the staining procedure). - Modifier
59: Indicates a distinct procedural service, used when multiple procedures are performed that are not normally reported together. - Modifier
91: Used for repeat clinical diagnostic laboratory tests on the same patient on the same day.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
| 207ZP0102X | Anatomic Pathology & Clinical Pathology |
| 207ZP0101X | Cytopathology |
| 207ZP0007X | Pathology |
| 207ZP0104X | Forensic Pathology |
| 207ZP0105X | Hematology |
These taxonomies represent specialties involved in the interpretation and performance of immunohistochemistry procedures.
Related Diagnoses
-
C50.911: Malignant neoplasm of unspecified site of right female breast- Relevant for cases where breast tissue is evaluated for malignancy using immunohistochemistry.
-
C61: Malignant neoplasm of prostate- Used when prostate tissue is analyzed for cancer markers via immunohistochemistry.
-
D49.2: Neoplasm of unspecified behavior of bone, soft tissue, and skin- Applicable when the behavior of a neoplasm in these tissues is unclear and immunohistochemistry aids in classification.
-
C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung- Used for lung or bronchial tissue specimens requiring immunohistochemical analysis to determine malignancy.
-
D05.10: Carcinoma in situ of unspecified breast- Relevant for breast tissue specimens where immunohistochemistry helps confirm carcinoma in situ.
-
C18.9: Malignant neoplasm of colon, unspecified- Used for colon tissue specimens analyzed for malignancy with immunohistochemical staining.
Related CPT Codes
-
88341: Each additional single antibody stain procedure- Used when more than one antibody stain is performed on the same specimen. Commonly billed together with
88342when multiple stains are required for diagnostic purposes.
- Used when more than one antibody stain is performed on the same specimen. Commonly billed together with
-
88360: Manual morphometric analysis- Used for manual quantitative analysis of stained slides, which may be performed in conjunction with
88342when detailed morphometric assessment is needed.
- Used for manual quantitative analysis of stained slides, which may be performed in conjunction with
Both 88341 and 88360 are related to 88342 in workflows where additional stains or quantitative analysis are necessary for comprehensive pathology evaluation.
National Reimbursement Benchmarks
For CPT 88342, the national mean rate for Medicare is $76.63, while the BUCA (average commercial) mean rate is $75.48. This shows that Medicare reimbursement is slightly higher than the commercial average for this code.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. Blue Cross Blue Shield has the widest spread at $65.91, indicating significant variability in rates. UnitedHealth Group has the tightest range at $34.33, suggesting more consistent reimbursement levels. Other payers, such as Aetna and Cigna, fall in between, with dispersions of $42.42 and $59.67, respectively.
The table and chart below present the full breakdown of national benchmarks for CPT 88342 across major payers.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.